Table 3.
Registered worldwide clinical trials with genetically engineered NK cells.
| Target | Sponsor and Clinicaltrials.gov identifier | Disease | Phase | Cell type |
|---|---|---|---|---|
| CD7—TCRζ, CD28, and 4-1BB | PersonGen BioTherapeutics, Suzhou, Jiangsu, China NCT02742727 |
Leukemia and lymphoma | Phase I/II | NK-92 cells |
| CD19/TCRζ/CD28 and 4-1BB | PersonGen BioTherapeutics, Suzhou, Jiangsu, China NCT02892695 |
Relapsed/refractory ALL, CLL, FL, BCL, DLBCL | Phase I/II | NK-92 cells |
| CD33/CD28/4-1BB | PersonGen BioTherapeutics, Suzhou, Jiangsu, China NCT02944162 |
Relapsed/refractory ALL | Phase I/II | NK-92 cells |
| MUC1 | PersonGen BioTherapeutics, Suzhou, Jiangsu, China NCT02839954 |
MUC1+ solid tumors | Phase I/II | Peripheral blood NK cells |
| CD19/4-1BB/CD18/iCasp9/IL-15 | MD Anderson Cancer Center, Houston, TX, USA NCT03056339 |
B cell malignancies | Phase I/II | Cord blood-derived NK cells |
| CD19/4-1BB/CD3ζ | National University of Singapore, Singapore NCT01974479 |
B-cell ALL | Phase I | Peripheral blood NK cells |
| CD19/4-1BB/CD3ζ | St. Jude's Children Research Hospital, Memphis, TN, USA NCT00995137 |
ALL | Phase I | Peripheral blood NK cells |
| NKG2D | The Third Affiliated Hospital of Guangzhou Medical University NCT03415100 |
Metastatic solid tumors | Phase I | Peripheral blood NK cells |
ALL: acute lymphoblastic leukemia; CLL: chronic lymphocytic leukemia; FL: follicular lymphoma; BCL: B cell lymphoma; MCL: mantle cell lymphoma; DLBCL: diffuse large cell lymphoma; AML: acute myeloid leukemia; NHL: non-Hodgkin Lymphoma.